Eli Lilly & Co. has announced a plan to invest at least $27 billion in building four manufacturing plants in the United States. This move comes as companies prepare for the potential impact of President Donald Trump’s tariffs. According to the company, three of these facilities will be dedicated to producing active ingredients for Lilly’s drugs, transferring essential processes typically conducted overseas back to the US. Additionally, another plant will be constructed to expand manufacturing capacity for Lilly’s pipeline of injectable drugs. This significant investment underscores the company’s commitment to strengthening domestic drug production capabilities. — news from Bloomberg
